-Ritonavir may reduce the efficacy of combined hormonal contraceptives; patients of childbearing potential using these products should be advised to use an effective alternative contraceptive method or an additional barrier method of contraception during therapy. ...
PAXLOVID (nirmatrelvir; ritonavir) co-packaged for oral use 300 mg;100 mg [see Dosage and Administration (2.2)]. • PAXLOVID (nirmatrelvir; ritonavir) co-packaged for oral use 150 mg;100 mg for patients with moderate renal impairment [see Dosage and Administration (2.3)]. Nirmatrelvir...
Learn about the FDA-approved oral Rx, PAXLOVID™, that can be used to treat mild-to-moderate COVID-19 in eligible adult patients. See risks & benefits.
Pfizer continues to gather pediatric data from the ongoing clinical trial, EPIC-Peds (Evaluation of Protease Inhibition for COVID-19 in Pediatric Patients) and intends to submit a supplemental New Drug Application (sNDA) to support the FDA approval of PAXLOVID in children at a future...
See risks & benefits. Learn about PAXLOVID™, an oral Rx that helps stop mild-to-moderate COVID-19 from becoming severe in adults with a high risk factor.
“At the same time, this agreement with the U.S. government makes it easier for patients to access Paxlovid; enables the United States to have a robust stockpile for future use; and provides Pfizer with greater clarity regarding the transition to a commercial market for this i...
performed a short term follow up on seven pregnant women of different gestational ages who received nirmatrelvir/ritonavir with a diagnosis of non-severe COVID-19 [58]. Of these seven patients, four with smaller gestational ages did not come to delivery in the time of follow up, and ...
While drug manufacturing carries a large carbon footprint, the steps taken to distribute medicines out of the factory and into patients’ hands also have a significant impact on the environment. One way by which distribution in pharma contributes to climate change is the use of cold chain shi...
Pfizer Inc. announced the submission of a New Drug Application to the U.S. Food and Drug Administration for approval of PAXLOVID™ for patients who are at high risk for progression to severe illness from COVID-19.
[12]Chourasia P., Maringanti B.S., Edwards-Fligner M., Gangu K., Bobba A., Sheikh A.B., Shekhar R. Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines-A Scoping Review. Vaccines. 2023;11:107. doi: 10.3390/vaccines11010107...